^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-A1403

    i
    Other names: SHR-A1403, HTI-1066
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Microtubule inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    2years
    A Study of SHR-A1403 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=9, Completed, Jiangsu HengRui Medicine Co., Ltd. | Unknown status --> Completed | N=30 --> 9
    Trial completion • Enrollment change • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    SHR-A1403